Lv6
2360 积分 2024-12-24 加入
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor
25天前
已完结
Discovery of Selective and Orally Bioavailable Heterobifunctional Degraders of Cyclin-Dependent Kinase 2
1个月前
已完结
Abstract 1553: Discovery of CDK4/6 bifunctional degraders for ER+/HER2- breast cancer andtriple negative breast cancer
1个月前
已关闭
Rational Approaches to Discovery of Orally Active and Brain-Penetrable Quinazolinone Inhibitors of Poly(ADP-ribose)polymerase
2个月前
已完结
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
2个月前
已完结
Targeting Ibrutinib-Resistant BTK-C481S Mutation with ARQ 531, a Reversible Non-Covalent Inhibitor of BTK
2个月前
已完结
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
2个月前
已完结
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2 H )-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors
2个月前
已完结
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models
2个月前
已完结
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
2个月前
已完结
皖公网安备34019202002308
